| 产品描述: | Lurbinectedin (PM01183, PM-1183, LY-01017, Tryptamicidin, Zepsyre, ZEPZELCA) 是一种 DNA minor groove 共价结合剂,具有强大的体外和体内的抗肿瘤活性。Lurbinectin 可抑制RMG1和RMG2细胞生长,对应的IC50值分别为1.25 nM和1.16 nM |
| 靶点: |
DNA minor groove; RMG2 cell growth(Cell-based assay):1.16 nM; RMG1 cell growth(Cell-based assay):1.25 nM |
| 体外研究: |
Lurbinectedin exhibits significant antitumor activity toward chemosensitive and chemoresistant CCC cells in vitro. Lurbinectedin plus SN-38 combination has strong synergistic effects on both the cisplatin-resistant and paclitaxel-resistant CCC cell lines |
| 体内研究: |
An examination of mouse CCC cell xenografts reveals that lurbinectedin significantly inhibits tumor growth. Lurbinectedin plus SN-38 combination results in a significant synergistic effect. Everolimus significantly enhances the antitumor activity of lurbinectedin-based chemotherapies |
| 细胞实验: |
Cell lines: The human ovarian CCC cell lines (RMG1, RMG2, KOC7C, HAC2) Concentrations: 0.1 nM, 0.3 nM, 1 nM, 3 nM Incubation Time: 48 h Method: CCC cells (2~5×105) are treated with lurbinectedin, SN38 or in combination of the two drugs at the indicated concentrations for 48 hours. Then, the cells are harvested and stained with PI and annexin V using the annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit, according to the manufacturer's instructions. Fluorescence data are collected using flow cytometry. The sum total of early apoptotic cells (annexin V(+), PI(−) cells) and late apoptotic cells (annexin V(+), PI(+) cells) is defined as the total number of apoptotic cells. The experiments are repeated at least three times. |
| 动物实验: |
Animal Models: 5- to 7-week-old nude mice Dosages: 0.180 mg/kg Administration: IV |
| 参考文献: |
1. Ryoko Takahashi, et al. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary. PLoS One. 2016 Mar 17;11(3):e0151050. 2. J F M Leal, et al. PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol. 2010 Nov;161(5):1099-110. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.274 ml |
6.37 ml |
12.741 ml |
| 5 mM |
0.255 ml |
1.274 ml |
2.548 ml |
| 10 mM |
0.127 ml |
0.637 ml |
1.274 ml |
| 50 mM |
0.025 ml |
0.127 ml |
0.255 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |